BioTuesdays

Author - Leonard Zehr

Catabasis Pharma
Markets

HCW starts Catabasis Pharma at buy

H.C. Wainwright initiated coverage of Catabasis Pharmaceuticals (NASDAQ:CATB) with a “buy” rating and $14 price target. The stock closed at $3.59 on Dec. 21. “The SMART Linker technology is key to our investment...

December 22, 2016
Arbutus Biopharma Logo
Developments

Arbutus, Spring Bank in HBV collaboration

Arbutus Biopharma (NASDAQ:ABUS) and Spring Bank Pharmaceuticals (NASDAQ:SBPH) agreed to perform collaborative preclinical studies in chronic Hepatitis B virus (HBV). The accord involves the co-administration of Spring...

December 19, 2016
Adamis Pharma
Developments

Adamis resubmits NDA to FDA for epinephrine pen

Adamis Pharmaceuticals (NASDAQ:ADMP) has resubmitted its NDA to the FDA for its Epinephrine Pre-filled Syringe (PFS) product candidate for the emergency treatment of anaphylaxis. The resubmission is intended to address...

December 16, 2016
IntelGenx Logo
Developments

IntelGenx, RedHill license Rizaport in Korea

IntelGenx (OTCQX:IGXT; TSX-V:IGX) and RedHill Biopharma (NASDAQ,:RDHL; TASE:RDHL) have signed an exclusive license agreement with Pharmatronic for the commercialization of Rizaport in South Korea. Rizaport is a...

December 14, 2016
ContraVir Logo
Developments

ContraVir updates action of HBV inhibitor

ContraVir Pharmaceuticals (NASDAQ:CTRV) provided new insights into the mechanism of action of its hepatitis B (HBV) cyclophilin inhibitor, CRV431, showing that it effectively blocks a critical interaction between HBV X...

December 8, 2016
Developments

MaRS and KHIDI in commercialization deal

MaRS Innovation and the Korea Health Industry Development Institute (KHIDI) signed a five-year global partnership agreement to commercialize the latest advances in biomedical and healthcare innovations, which is...

December 1, 2016
oramed
Developments

Oramed GLP-1 analog found safe in study

Oramed Pharmaceuticals (NASDAQ:ORMP) has successfully concluded a Phase 1b study of ORMD-0901, its oral GLP-1 analog, in Type 2 diabetes patients. The study showed ORMD-0901 to be safe and well tolerated, having no...

November 29, 2016